{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:18:33Z","timestamp":1758633513860},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>AbbVie's 3 direct\u2010acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Safe and efficacious antiviral regimens resulting in minimal to no drug\u2013drug interactions (DDIs) with antiretrovirals are needed to ensure that patients coinfected with HCV and the human immunodeficiency virus (HIV) achieve 12\u2010week sustained virologic response rates similar to HCV\u2010monoinfected patients. Also, the prevalence of injection drug use history is high in both monoinfected and HIV\/HCV\u2010coinfected patients. This review summarizes results from phase 1 DDI studies of the 3D regimen and antiretrovirals or drugs to treat substance abuse. Data suggest the 3D regimen is a viable option for HIV\/HCV\u2010coinfected patients on antiretroviral therapy containing tenofovir\/emtricitabine, abacavir\/lamivudine, dolutegravir, raltegravir, or atazanavir. HCV\u2010infected patients receiving medications for substance abuse, particularly methadone or buprenorphine\/naloxone, can also be treated with the 3D regimen.<\/jats:p>","DOI":"10.1002\/cpdd.327","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T15:25:23Z","timestamp":1488813923000},"page":"201-205","source":"Crossref","is-referenced-by-count":11,"title":["Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs for Substance Abuse"],"prefix":"10.1002","volume":"6","author":[{"given":"Jennifer R.","family":"King","sequence":"first","affiliation":[{"name":"AbbVie, Clinical Pharmacology and Pharmacometrics  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev M.","family":"Menon","sequence":"additional","affiliation":[{"name":"AbbVie, Clinical Pharmacology and Pharmacometrics  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Viekira Pak (ombitasvir paritaprevir and ritonavir tablets; dasabuvir tablets) [prescribing information] 2015 AbbVie Inc North Chicago IL"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1213"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02605-15"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00795-16"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.07.008"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016196"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00292-13"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048918"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp4001348"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282faa71e"},{"key":"e_1_2_7_15_1","unstructured":"Edurant (rilpivirine) [prescribing information] 2015 Janssen Therapeutics Titusville NJ"},{"key":"e_1_2_7_16_1","unstructured":"M Ahmed A Polepally R Menon 2016"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.026"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029546"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.029"},{"key":"e_1_2_7_20_1","unstructured":"DAJ Bow J Liu O Kavetskaia 2014"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.026"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0317-8"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2125.1997.00644.x","article-title":"Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir","volume":"44","author":"Eagling VA","year":"1997","journal-title":"Br J Clin Pharmacol."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.038646"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/js980197h"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2011.03.015"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3028"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:21:44Z","timestamp":1696616504000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/cpdd.327"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.327","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}